학술논문
Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Document Type
Article
Author
Boslem, Ebru; Reibe, Saskia; Carlessi, Rodrigo; Smeuninx, Benoit; Tegegne, Surafel; Egan, Casey L.; McLennan, Emma; Terry, Lauren V.; Nobis, Max; Mu, Andre; Nowell, Cameron; Horadagoda, Neil; Mellett, Natalie A.; Timpson, Paul; Jones, Matthew; Denisenko, Elena; Forrest, Alistair R. R.; Tirnitz-Parker, Janina E. E.; Meikle, Peter J.; Rose-John, Stefan
Source
Subject
Language
ISSN
2375-2548
Abstract
The article discusses the rising incidence of hepatocellular carcinoma (HCC), a fatal type of liver cancer, which is closely associated with metabolic diseases like metabolic dysfunction-associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH). While current treatments for HCC are limited in effectiveness, there is a growing need for strategies to prevent and combat NASH-induced HCC, as lifestyle interventions and weight reduction remain the primary preventive measures.